Kalaris Therapeutics Inc.(KLRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KLRS Kalaris Therapeutics Inc.

Post-Mkt 08-17 19:47:18 EDT

3.96

-0.12

-2.94%

盘后3.96

+0.000.00%

19:34 EDT

High4.17	Low3.91	Vol30.10K
Open4.05	D1 Closing4.08	Amplitude6.33%
Mkt Cap94.22M	Tradable Cap28.63M	Total Shares23.79M
T/O120.57K	T/O Rate0.42%	Tradable Shares7.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":3.96,"timestamp":1786996800000,"preClose":4.08,"halted":0,"volume":30096,"hourTrading":{"tag":"盘后","latestPrice":3.96,"preClose":3.96,"latestTime":"19:34 EDT","volume":75,"amount":297,"timestamp":1787009649532,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.029411764705882377,"floatShares":7230800,"shares":23792278,"eps":-2.064571,"marketStatus":"Post-Mkt","change":-0.12,"latestTime":"08-17 19:47:18 EDT","open":4.05,"high":4.17,"low":3.9116,"amount":120573.00288000001,"amplitude":0.063333,"askPrice":4.67,"askSize":100,"bidPrice":3.73,"bidSize":19,"shortable":3,"etf":0,"ttmEps":-2.064571,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787011200000},"marketStatusCode":4,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":4.08,"preHourTrading":{"tag":"盘前","latestPrice":4.01,"preClose":4.08,"latestTime":"08:57 EDT","volume":112,"amount":430.119984,"timestamp":1786971444487,"change":-0.07,"changeRate":-0.017157,"amplitude":0.132353},"postHourTrading":{"tag":"盘后","latestPrice":3.96,"preClose":3.96,"latestTime":"19:34 EDT","volume":75,"amount":297,"timestamp":1787009649532,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.701516},"requestUrl":"/m/hq/s/KLRS","defaultTab":"news","newsList":[{"id":"2658915620","title":"Kalaris Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658915620","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658915620?lang=en_us&edition=fundamental","pubTime":"2026-08-11 21:32","pubTimestamp":1786455159,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryKalaris Therapeutics IncKLRS.OQreported a quarterly adjusted loss of 48 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N4481C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990904","title":"Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990904","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990904?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:14","pubTimestamp":1786450451,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Kalaris Therapeutics Inc Q2 operating expenses USD 12.386 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 11-AUG-202612:01:02.89 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nRSD85GTrC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990564","title":"Kalaris Net Loss Widens to $11.52 Million in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990564","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990564?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:04","pubTimestamp":1786449868,"startTime":"0","endTime":"0","summary":"Kalaris net loss widens to $11.52 million in Q2 FY26Kalaris Therapeutics posted a GAAP net loss of USD 11.52 million, versus a GAAP net loss of USD 11.35 million a year earlier.GAAP R&D expense rose 6","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL4bg18R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","KLRS","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","BCDF","LU2210149790.SGD","NDAQ","IE00BGHQF748.EUR","BK4139","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658099084","title":"Press Release: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2658099084","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658099084?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:01","pubTimestamp":1786449660,"startTime":"0","endTime":"0","summary":"reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment. -- New manufacturing batch completed including process enhancements that. have further reduced already low levels of process impurities.-- Kalaris is currently conducting a Phase 1b/2, multi-ascending dose,The study aims to assess the safety and efficacy of repeat doses of TH103. at different dose levels and to identify the optimal dose and regimen for. potential Phase 3 development. Preliminary data from the Phase 1b/2 study. is expected in the first half of 2027.-- As previously announced, Kalaris expanded its leadership team with the. hire of Liisa Bayko as Chief Financial Officer. Ms. Bayko brings more. than two decades of experience in biotechnology finance, strategy, and. capital markets, most recently serving as Managing Director and Senior. Biotechnology Analyst at Evercore ISI, where she was consistently. recognized as one of the industry's top-ranked analysts covering small-. -- As announced recently, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","IDNA","BMED","BK4139","KLRS","NVIB","HYLG","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658990580","title":"Kalaris Therapeutics Inc Q2 EPS USD -0.48 VS. Ibes Estimate USD -0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2658990580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658990580?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXVZKFR1:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658970309","title":"Kalaris Therapeutics Inc Q2 Operating Expenses USD 12.386 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658970309","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658970309?lang=en_us&edition=fundamental","pubTime":"2026-08-11 20:00","pubTimestamp":1786449602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nPLXVZKFR1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640073","title":"Kalaris Therapeutics Inc Expected to Post a Loss of 49 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640073","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657640073?lang=en_us&edition=fundamental","pubTime":"2026-08-08 01:04","pubTimestamp":1786122245,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc <KLRS.OQ> expected to post a loss of49cents a share - Earnings PreviewKalaris Therapeutics IncKLRS.OQKLRS.Ois expected to  show no change in quarterly revenue when it reports ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N44426I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656309779","title":"Kalaris Therapeutics Director Laurie Keating Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2656309779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656309779?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:02","pubTimestamp":1785787364,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics director Laurie Keating files initial beneficial ownership statementKalaris Therapeutics director Laurie Keating filed an initial Form 3 on Aug. 3 covering her holdings as of Aug. 1.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLtgNY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654231040","title":"Kalaris Therapeutics’ Amy O’Leary Vandekop, Associate VP and Corporate Controller, Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2654231040","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654231040?lang=en_us&edition=fundamental","pubTime":"2026-07-28 04:05","pubTimestamp":1785182757,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics’ Amy O’Leary Vandekop, associate VP and corporate controller, files initial beneficial ownership statementKalaris Therapeutics officer Amy O’Leary Vandekop reported 948 common sha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDLbstw9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653246932","title":"Kalaris Therapeutics Files Form 3 for CFO Liisa Ann Bayko","url":"https://stock-news.laohu8.com/highlight/detail?id=2653246932","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653246932?lang=en_us&edition=fundamental","pubTime":"2026-07-21 04:59","pubTimestamp":1784581187,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics files Form 3 for CFO Liisa Ann BaykoKalaris Therapeutics filed a Form 3 for Liisa Ann Bayko, naming her chief financial officer in an initial insider ownership disclosure dated Ju","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL3qs2kJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652421383","title":"Kalaris Therapeutics Names Liisa Bayko as CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2652421383","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652421383?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:02","pubTimestamp":1784548965,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics names Liisa Bayko as CFOKalaris Therapeutics appointed Liisa Bayko as chief financial officer as it advances clinical development of TH103 for neovascular age-related macular dege","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL4MZ0qj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","KLRS","BCDF","LU2210150020.SGD","SG9999014021.USD","IE00BKPKM429.USD","BK4139","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4112","SG9999014039.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652218796","title":"Kalaris Therapeutics - Appoints Liisa Bayko as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652218796","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652218796?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548835,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nFWN43M0MU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652521800","title":"Press Release: Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2652521800","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652521800?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:00","pubTimestamp":1784548800,"startTime":"0","endTime":"0","summary":"Strategic finance leader with over 20+ years of experience in the biotechnology spaceCFO hire bolsters Kalaris' leadership team and supports continued growth of the company as it enrolls its Phase 1b/","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","BK4139","KLRS","BK4120"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652282784","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2652282784","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652282784?lang=en_us&edition=fundamental","pubTime":"2026-07-18 01:51","pubTimestamp":1784310676,"startTime":"0","endTime":"0","summary":"Travelers'  Q2 earnings unexpectedly increased year over year, while the property and casualty insurer's written premiums came in ahead of market estimates.Shares jumped 8.3% as intraday trading volume climbed to over 2.38 million from a daily average of about 1.70 million.Kalaris Therapeutics  said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.Shares surged 18% as intraday trading volume jumped to over 9.83 million from a daily average of about 79,000.Callan JMB's  shares rose 40% amid heavy trading after the company announced a partnership with Alabama State University to support the development of an integrated pharmaceutical manufacturing ecosystem.More than 41.8 million shares of the company traded intraday, compared with a daily average of about 373,000.Price: 365.63, Change: +27.81, Percent Change: +8.23","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BKVL7J92.USD","BK4107","CJMB","BK4533","KLRS","TRV","KBWP","BK4588","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","IAK","BK4585","BK4139","BK4131"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652282797","title":"Why Is Kalaris Therapeutics Stock Gaining Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652282797","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652282797?lang=en_us&edition=fundamental","pubTime":"2026-07-18 01:31","pubTimestamp":1784309460,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics, Inc.  announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration.Following the announcement, the stock jumped nearly 18%.The clinical-stage biopharmaceutical company stated that the updated data build on previous findings by showing vision improvements and enhanced retinal anatomy.The expanded study analyzed 17 treatment-naive individuals and three treatment-experienced individuals, tracking all 20 participants through a six-month follow-up window.The expanded efficacy analysis continued to show robust structural and functional progress.Data regarding TH103 plasma pharmacokinetics suggested strong intraocular retention.The candidate exhibited a 27- to 53-fold lower maximum plasma concentration on a molar equivalence basis compared to existing leading anti-VEGF products.The increased retention supports the company’s hypothesis that prolonged biological activity can extend ","market":"sh","thumbnail":"https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/17/Close-Up-Hands-Of-Ophthalmologist-With-E.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/cdn-cgi/image/width=3840,format=auto,quality=85/files/images/story/2026/07/17/Close-Up-Hands-Of-Ophthalmologist-With-E.jpg"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/07/60532843/why-is-kalaris-therapeutics-stock-gaining-friday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/07/60532843/why-is-kalaris-therapeutics-stock-gaining-friday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4539","KLRS","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652282944","title":"Why Is Kalaris Therapeutics (KLRS) Up Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2652282944","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652282944?lang=en_us&edition=fundamental","pubTime":"2026-07-18 01:08","pubTimestamp":1784308114,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics stock rallied after the company provided investors with updated clinical trial data.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/why-is-penny-stock-kalaris-therapeutics-klrs-up-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/why-is-penny-stock-kalaris-therapeutics-klrs-up-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284287","title":"Analyst Maintains Buy on KLRS as TH103’s Emerging nAMD Data Highlight Rapid Efficacy and Differentiated Durability","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652284287?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:15","pubTimestamp":1784304939,"startTime":"0","endTime":"0","summary":"William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on KLRS stock, giving a Buy rating today. Lachlan Hanbury Brown has...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-klrs-as-th103s-emerging-namd-data-highlight-rapid-efficacy-and-differentiated-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-klrs-as-th103s-emerging-namd-data-highlight-rapid-efficacy-and-differentiated-durability-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652940075","title":"Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2652940075","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652940075?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:44","pubTimestamp":1784288672,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics  said Friday that additional patients from its phase 1a trial of TH103 in neovascular age-related macular degeneration showed improvements in vision and retinal anatomy.The expanded dataset includes 17 treatment-naive patients and three treatment-experienced patients in the safety cohort, with all 20 patients completing six months of follow-up, according to the company.Kalaris said the expanded efficacy analysis showed \"robust\" structural and functional improvements, and no cases of intraocular inflammation were noted among six patients treated with the 2.5 mg dose using product manufactured after process adjustments to reduce impurities.The company said it continues to enroll and dose patients in an ongoing phase 1b/2 study evaluating a standard four-dose loading regimen of TH103 in treatment-naive patients using an ascending-dose design.Kalaris said it expects to report initial data from the phase 1b/2 study in H1 of 2027.Shares of Kalaris Therapeutics were down ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652140711","title":"Kalaris Reports Positive Phase 1a Data for TH103 in Neovascular AMD Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2652140711","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652140711?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286044,"startTime":"0","endTime":"0","summary":"Kalaris reports positive Phase 1a data for TH103 in neovascular AMD studyKalaris reported positive expanded Phase 1a single-ascending-dose data for TH103 in neovascular AMD, supporting potential longe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL3wsFmK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","LU0314104364.USD","SG9999014021.USD","NDAQ","LU2095319765.USD","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU2210149790.SGD","BK4588","KLRS","BK4139","BCDF","IE00BKPKM429.USD","SG9999014013.SGD","SG9999014005.SGD","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652485407","title":"Kalaris Therapeutics - TH103 Demonstrates 27- to 53-fold Lower Cmax vs Leading Anti-vegf Agents","url":"https://stock-news.laohu8.com/highlight/detail?id=2652485407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652485407?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kalaristx.com","stockEarnings":[{"period":"1week","weight":0.0025},{"period":"1month","weight":-0.1535},{"period":"3month","weight":-0.1673},{"period":"6month","weight":-0.5283},{"period":"1year","weight":0.7974},{"period":"ytd","weight":-0.5166}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.034153},{"month":2,"riseRate":0.833333,"avgChangeRate":0.085302},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.271732},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.108864},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.115676},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.099519},{"month":7,"riseRate":0.5,"avgChangeRate":0.0008},{"month":8,"riseRate":0.857143,"avgChangeRate":0.232936},{"month":9,"riseRate":0.666667,"avgChangeRate":0.05708},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.080715},{"month":11,"riseRate":0.666667,"avgChangeRate":0.065433},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.187434}],"exchange":"NASDAQ","name":"Kalaris Therapeutics Inc.","nameEN":"Kalaris Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kalaris Therapeutics Inc.(KLRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kalaris Therapeutics Inc.(KLRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kalaris Therapeutics Inc.,KLRS,Kalaris Therapeutics Inc.股票,Kalaris Therapeutics Inc.股票老虎,Kalaris Therapeutics Inc.股票老虎国际,Kalaris Therapeutics Inc.行情,Kalaris Therapeutics Inc.股票行情,Kalaris Therapeutics Inc.股价,Kalaris Therapeutics Inc.股市,Kalaris Therapeutics Inc.股票价格,Kalaris Therapeutics Inc.股票交易,Kalaris Therapeutics Inc.股票购买,Kalaris Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kalaris Therapeutics Inc.(KLRS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kalaris Therapeutics Inc.(KLRS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction